Cuál es el precio por Sesen Bio, Inc. (SESN)

Precio por Sesen Bio, Inc. (SESN) es de$0.6288

Cuál es la capitalización de mercado por Sesen Bio, Inc. (SESN)

Capitalización de mercado por Sesen Bio, Inc. (SESN) es $6.00M

Sesen Bio, Inc. (SESN) Ratio P/E

Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Año	Ratio P/E	Cambiar
Not enough data for the provided dates.

Año

Ratio P/E

Cambiar

Not enough data for the provided dates.

Empresa	P/E Ratio	Diferencia del P/E Ratio	País
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	18.38	-	BE

Empresa

P/E Ratio

Diferencia del P/E Ratio

País